Evidence map›Paper›PMID 24429318›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2014

Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.

A P Trollip, D Moore, J Coronel, L Caviedes, S Klages, T Victor, E Romancenco, V Crudu, K Ajbani, V P Vineet and 9 more

Open access · greenAbstract readComparative StudyMulticenter Study
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 6 countries.

A P TrollipBiomedical Sciences, Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Medical Research Council Centre for Molecular and Cellular Biology, Stellenbosch University, Cape Town, South Africa.
D MooreTB Centre and Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
J CoronelLaboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
L CaviedesLaboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru.
S KlagesBiomedical Sciences, Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Medical Research Council Centre for Molecular and Cellular Biology, Stellenbosch University, Cape Town, South Africa.
T VictorBiomedical Sciences, Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Medical Research Council Centre for Molecular and Cellular Biology, Stellenbosch University, Cape Town, South Africa.
E RomancencoMicrobiology and Morphology Laboratory, Phthisiopneumology Institute, Chisinau, Moldova.
V CruduMicrobiology and Morphology Laboratory, Phthisiopneumology Institute, Chisinau, Moldova.
K AjbaniDepartment of Microbiology, Parmanand Deepchand Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India.
V P VineetDepartment of Microbiology, Parmanand Deepchand Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India.
C RodriguesDepartment of Microbiology, Parmanand Deepchand Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India.
R L JacksonUniversity of California San Diego School of Medicine, La Jolla, California, USA.
K EisenachDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
R S GarfeinUniversity of California San Diego School of Medicine, La Jolla, California, USA.
T C RodwellDivision of Global Public Health, University of California San Diego School of Medicine, La Jolla, California, USA.
E DesmondMycobacteriology and Mycology Section, Microbial Diseases Laboratory, California Department of Public Health, Richmond, California, USA.
E J GroesslUniversity of California San Diego, Veterans' Affairs San Diego Healthcare System, La Jolla, California, USA.
T G GaniatsUniversity of California San Diego Health Services Research Center, UCSD, La Jolla, California, USA.
A CatanzaroUniversity of California San Diego School of Medicine, La Jolla, California, USA.
University of California, San Diego · USUniversidad Peruana Cayetano Heredia · PENational Hospital · INPhthisiopneumology Institute "Chiril Draganiuc" · MDStellenbosch University · ZACalifornia Department of Public Health · USNational Research Foundation · ZAP. D. Hinduja Hospital and Medical Research Centre · INUniversity of Arkansas for Medical Sciences · USVA San Diego Healthcare System · US

Funding

Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant TuberculosisU01AI082229 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CATANZARO, ANTONINO · 2009 to 2013
$10.9M
Binational Transmission of Multidrug-Resistant Tuberculosis, California & MexicoK01AI083784 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2009 to 2012
$487k
NIAID NIH HHS 5U01-AI082229NIAID NIH HHS K01 AI083784NIAID NIH HHS K01-AI083784NIAID NIH HHS U01 AI082229
6 · The paper itself

Abstract

objectiveTo establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay.

settingA multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa.

designIn the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum.

resultsBreakpoints for MFX (0.5 μg/ml), OFX (1 μg/ml), AMK (2 μg/ml), KM (5 μg/ml) and CPM (2.5 μg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low.

conclusionMODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test.

Indexed as

Drug Resistance, Multiple, BacterialMicroscopyAmikacinAntitubercular AgentsCapreomycinFluoroquinolonesHumansIndiaKanamycinMicrobial Sensitivity TestsMoldovaMoxifloxacinMycobacterium tuberculosisOfloxacinPeruPredictive Value of TestsAmikacinAntitubercular AgentsCapreomycinFluoroquinolonesKanamycinMoxifloxacinOfloxacin

Identifiers

PMID24429318
PMCPMC4250530
OpenAlexW1999616279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.